Biankin, A. V. , Piantadosi, S. and Hollingsworth, S. J. (2015) Patient-centric trials for therapeutic development in precision oncology. Nature, 526, pp. 361-370. (doi: 10.1038/nature15819) (PMID:26469047)
|
Text
109388.pdf 2MB |
Abstract
An enhanced understanding of the molecular pathology of disease gained from genomic studies is facilitating the development of treatments that target discrete molecular subclasses of tumours. Considerable associated challenges include how to advance and implement targeted drug-development strategies. Precision medicine centres on delivering the most appropriate therapy to a patient on the basis of clinical and molecular features of their disease. The development of therapeutic agents that target molecular mechanisms is driving innovation in clinical-trial strategies. Although progress has been made, modifications to existing core paradigms in oncology drug development will be required to realize fully the promise of precision medicine.
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Biankin, Professor Andrew |
| Authors: | Biankin, A. V., Piantadosi, S., and Hollingsworth, S. J. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences |
| Journal Name: | Nature |
| Publisher: | Nature Publishing Group |
| ISSN: | 0028-0836 |
| ISSN (Online): | 1476-4687 |
| Copyright Holders: | Copyright © 2015 The London School of Economics and Political Science |
| First Published: | First published in Nature 526:361-370 |
| Publisher Policy: | Reproduced in accordance with the copyright policy of the publisher |
University Staff: Request a correction | Enlighten Editors: Update this record
Deposit and Record Details
Deposit and Record Details